The diagnosis and treatment of antisynthetase syndrome

Clinical Pulmonary Medicine

Volumn 23, Issue 5, 2016, Pages 218-226

  Witt, Leah J ^a   Curran, James J ^a   Strek, Mary E ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Antisynthetase syndrome; Connective tissue disease; Idiopathic inflammatory myopathies; Immunosuppression; Interstitial lung disease

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; MYCOPHENOLATE MOFETIL; RITUXIMAB; TACROLIMUS;

ANTISYNTHETASE SYNDROME; ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG BIOPSY; META ANALYSIS (TOPIC); PULMONARY HYPERTENSION; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL; SYSTEMATIC REVIEW (TOPIC);

EID: 84987740611     PISSN: 10680640     EISSN: 15365956     Source Type: Journal    
DOI: 10.1097/CPM.0000000000000171     Document Type: Article

References (69)

1. Connors GR, Christopher-Stine L, Oddis CV, et al. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest. 2010;138:1464-1474.
2. Kalluri M, Oddis CV. Pulmonary manifestations of the idiopathic inflammatory myopathies. Clin Chest Med. 2010;31:501-512.
3. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344-347.
4. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403-407.
5. Mathews MB, Reichlin M, Hughes G, et al. Anti-Threonyl-TRNA synthetase, a second myositis-related autoantibody. J Exp Med. 1984;160:420-434.
6. Mathews MB, Bernstein RM. Myositis autoantibody inhibits histidyl-TRNA synthetase: A model for autoimmunity. Nature. 1983;304:177-179.
7. Marguerie C, Bunn C, Beynon H, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-TRNA synthetase enzymes. QJM. 1990;77:1019-1038.
8. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositisspecific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991;70:360-374.
9. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. The Lancet. 2003;362:971-982.
10. Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. Jornal Brasileiro de Pneumologia. 2011;37:100-109.
11. Watanabe K, Handa T, Tanizawa K, et al. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med. 2011;105:1238-1247.
12. Stone KB, Oddis CV, Fertig N, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 2007;56:3125-3131.
13. Hervier B, Meyer A, Dieval C, et al. Pulmonary hypertension in antisynthetase syndrome: prevalence, etiology and survival. Eur Respir J. 2013;42:1271-1282.
14. Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies againstaminoacyl-TRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum. 1996;26:459-467.
15. Targoff I. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 2002;28:859.
16. Bahmer T, Romagnoli M, Girelli F, et al. The use of auto-Antibody testing in the evaluation of interstitial lung disease (ILD)-A practical approach for the pulmonologist. Respir Med. 2016;113:80-92.
17. Chen Z, Cao M, Plana MN, et al. Utility of anti-melanoma differentiation-Associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: A review of the literature and a meta-Analysis. Arthritis Care Res. 2013;65: 1316-1324.
18. La Corte, R, Lo Monaco, A, Locaputo A, et al. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity. 2006;39:249-253.
19. Mileti LM, Strek ME, Niewold TB, et al. Clinical characteristics of patients with anti-Jo-1 antibodies: A single center experience. J Clin Rheumatol. 2009;15:254-255.
20. Ghirardello A, Zampieri S, Tarricone E, et al. Clinical implications of autoantibody screening in patients with autoimmune myositis. Autoimmunity. 2006;39:217-221.
21. Dugar M, Cox S, Limaye V, et al. Clinical heterogeneity and prognostic features of South Australian patients with antisynthetase autoantibodies. Intern Med J. 2011;41:674-679.
22. Wakasugi K, Schimmel P. Two distinct cytokines released from a human aminoacyl-TRNA synthetase. Science. 1999;284:147-151.
23. Ascherman D. Role of Jo-1 in the Immunopathogenesis of the antisynthetase syndrome. Curr Rheumatol Rep. 2015;17:1-7.
24. Hamaguchi Y, Fujimoto M, Matsushita T, et al. Common and distinct clinical features in adult patients with anti-AminoacyltRNA synthetase antibodies: heterogeneity within the syndrome. PloS one. 2013;8:e60442.
25. Marie I, Josse S, Decaux O, et al. Comparison of long-Term outcome between anti-Jo1-And anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev. 2012;11:739-745.
26. Debray M-P, Borie R, Revel M-P, et al. Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings. Eur J Radiol. 2015;84:516-523.
27. Travis WD, Costabel U, Hansell DM, et al. An Official American Thoracic Society/European Respiratory Society Statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733-748.
28. Yousem SA, Gibson K, Kaminski N, et al. The pulmonary histopathologic manifestations of the anti-Jo-1 tRNA synthetase syndrome. Mod Pathol. 2010;23:874-880.
29. Yousem SA, Schneider F, Bi D, et al. The pulmonary histopathologic manifestations of the anti-PL7/antithreonyl transfer RNA synthetase syndrome. Hum Pathol. 2014;45:1199-1204.
30. Mochimaru H, Kawamoto M, Enomoto T, et al. Transbronchial biopsy is clinically useful in classifying patients with interstitial pneumonia associated with polymyositis and dermatomyositis. Respirology. 2008;13:863-870.
31. Dalakas MC. Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin North Am. 2002;28:779-798.
32. Kenney K, Landau ME, Gonzalez RS, et al. Serum creatine kinase after exercise: drawing the line between physiological response and exertional rhabdomyolysis. Muscle Nerve. 2012;45: 356-362.
33. Baughman RP, Meyer KC, Nathanson I, et al. Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;142:e1S-e111S.
34. Meyer KC, Bierach J. Immunosuppressive therapy for autoimmune lung diseases. Immunol Allergy Clin North Am. 2012;32: 633-669.
35. Vananuvat P, Suwannalai P, Sungkanuparph S, et al. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum. 2011;41: 497-502.
36. Perrillo RP, Martin P, Lok AS. Preventing hepatitis B reactivation due to immunosuppressive drug treatments. Jama. 2015;313: 1617-1618.
37. Hench PS, Kendall EC, Slocumb CH, et al. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions: A study in clinical physiology. Arch Intern Med. 1950;85:545-666.
38. Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993;94:379-387.
39. Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9:30.
40. Marie I, Hatron P, Dominique S, et al. Short-Term and long-Term outcomes of interstitial lung disease in polymyositis and dermatomyositis: A series of 107 patients. Arthritis Rheum. 2011;63: 3439-3447.
41. Bunch TW, Worthington JW, Combs JJ, et al. Azathioprine with prednisone for PolymyositisA Controlled, Clinical Trial. Ann Intern Med. 1980;92:365-369.
42. Bunch TW. Prednisone and azathioprine for polymyositis. Longterm followup. Arthritis Rheum. 1981;24:45-48.
43. Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006;130:30-36.
44. Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-Associated interstitial lung disease. J Rheumatol. 2013;40:640-646.
45. Robaeys G, Cassiman D, Verslype C, et al. Successful conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic) in liver transplant patients with gastrointestinal side effects. Transplant Proc. 2009;41:610-613.
46. Klein IH, Abrahams A, van Ede T, et al. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation. 2002;73:732-736.
47. Cavagna L, Caporali R, Abdì-Alì L, et al. Cyclosporine in anti- Jo1-positive patients with corticosteroid-refractory interstitial lung disease. J Rheumatol. 2013;40:484-492.
48. Oddis CV, Sciurba FC, Elmagd KA, et al. Tacrolimus in refractory poly myositis with inter stitial lung disease. Lancet. 1999;353: 1762-1763.
49. Matsubara S, Kondo K, Sugaya K, et al. Effects of tacrolimus on dermatomyositis and polymyositis: A prospective, open, nonrandomized study of nine patients and a review of the literature. Clin Rheumatol. 2012;31:1493-1498.
50. Witt LJ, Demchuck C, Curran JJ, et al. Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease. Pulm Pharmacol Ther. 2016;36:46-52.
51. Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-Associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005;52:2439-2446.
52. Oddis CV, Reed AM, Aggarwal R, et al. the RIMSG. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314-324.
53. Sem M, Molberg Ø, Lund MB, et al. Rituximab treatment of the anti-synthetase syndrome-A retrospective case series. Rheumatology. 2009;48:968-971.
54. Keir GJ, Maher TM, Hansell DM, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J. 2012;40:641-648.
55. Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatmentrefractory interstitial lung disease. Respirology. 2014;19:353-359.
56. Ge Y, Peng Q, Zhang S, et al. Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: A systematic review. Clin Rheumatol. 2015;34:99-105.
57. Mira-Avendano IC, Parambil JG, Yadav R, et al. A retrospective review of clinical features and treatment outcomes in steroidresistant interstitial lung disease from polymyositis/dermatomyositis. Respir Med. 2013;107:890-896.
58. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of highdose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993-2000.
59. Bakewell CJ, Raghu G. Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest. 2011;139:441-443.
60. Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J. 2000;15:373-381.
61. Rozelle A, Trieu S, Chung L. Malignancy in the setting of the anti-synthetase syndrome. J Clin Rheumatol. 2008;14: 285-288.
62. Legault D, McDermott J, Crous-Tsanaclis AM, et al. Cancerassociated myositis in the presence of anti-Jo1 autoantibodies and the antisynthetase syndrome. J Rheumatol. 2008;35:169-171.
63. Castañeda-Pomeda M, Prieto-González S, Grau JM. Antisynthetase syndrome and malignancy: our experience. J Clin Rheumatol. 2011;17:458.
64. Hervier B, Devilliers H, Stanciu R, et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-TRNA synthetase antibody specificity. Autoimmun Rev. 2012;12:210-217.
65. Zang Y-S, Xiu Q-Y, Fang Z, et al. Case report: dramatic recovery of lung adenocarcinoma-Associated dermatomyositis with targeted lung cancer therapy alone. Oncologist. 2008;13:79-81.
66. Aggarwal R, Cassidy E, Fertig N, et al. Patients with non-Jo-1 anti-TRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis. 2014;73:227-232.
67. Fischer A, Swigris JJ, du Bois RM, et al. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med. 2009;103: 1719-1724.
68. Lega J-C, Fabien N, Reynaud Q, et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: A meta-Analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev. 2014;13:883-891.
69. Rojas-Serrano J, Herrera-Bringas D, Mejía M, et al. Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD). Clin Rheumatol. 2015;34:1563-1569.